Berkshire Hathaway Inc Purchases Shares of 28,880,209 DaVita Inc. $DVA

Berkshire Hathaway Inc purchased a new stake in shares of DaVita Inc. (NYSE:DVA - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 28,880,209 shares of the company's stock, valued at approximately $6,425,269,000. DaVita comprises about 2.1% of Berkshire Hathaway Inc's investment portfolio, making the stock its 11th biggest holding. Berkshire Hathaway Inc owned approximately 45.27% of DaVita as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in DVA. BlackRock Inc. bought a new stake in DaVita during the second quarter valued at approximately $547,520,000. Arrowstreet Capital Limited Partnership raised its position in DaVita by 114.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company's stock worth $135,196,000 after acquiring an additional 636,191 shares during the period. Bank of New York Mellon Corp purchased a new position in shares of DaVita during the 2nd quarter worth $101,127,000. Norges Bank purchased a new position in shares of DaVita during the 4th quarter worth $49,164,000. Finally, Corient Private Wealth LLC grew its position in shares of DaVita by 1,493.1% during the 4th quarter. Corient Private Wealth LLC now owns 358,299 shares of the company's stock valued at $40,706,000 after acquiring an additional 335,809 shares during the period. Hedge funds and other institutional investors own 90.12% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on DVA shares. Barclays upped their price objective on DaVita from $218.00 to $224.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 5th. TD Cowen raised DaVita from a "hold" rating to a "buy" rating and boosted their price target for the company from $201.00 to $220.00 in a report on Friday, August 7th. UBS Group upped their price target on DaVita from $235.00 to $270.00 and gave the stock a "buy" rating in a research report on Friday, July 10th. Oppenheimer set a $220.00 price objective on DaVita in a research note on Friday, August 7th. Finally, Truist Financial lowered their price objective on DaVita from $250.00 to $215.00 and set a "hold" rating on the stock in a research report on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, DaVita currently has a consensus rating of "Hold" and an average price target of $221.75.

Insider Activity at DaVita

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the business's stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the transaction, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.90% of the stock is owned by insiders.

DaVita Price Performance

Shares of DVA stock opened at $180.34 on Thursday. The company has a market capitalization of $11.51 billion, a price-to-earnings ratio of 14.76, a PEG ratio of 0.59 and a beta of 0.88. DaVita Inc. has a one year low of $101.00 and a one year high of $247.49. The company's fifty day moving average price is $213.07 and its 200-day moving average price is $182.80.

DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating analysts' consensus estimates of $3.88 by $0.14. The company had revenue of $3.55 billion for the quarter, compared to analysts' expectations of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. DaVita's revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities research analysts expect that DaVita Inc. will post 14.57 earnings per share for the current fiscal year.

DaVita Company Profile

DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source